BR112017028331A2 - proteínas de fusão que se ligam a receptores fc humanos - Google Patents

proteínas de fusão que se ligam a receptores fc humanos

Info

Publication number
BR112017028331A2
BR112017028331A2 BR112017028331A BR112017028331A BR112017028331A2 BR 112017028331 A2 BR112017028331 A2 BR 112017028331A2 BR 112017028331 A BR112017028331 A BR 112017028331A BR 112017028331 A BR112017028331 A BR 112017028331A BR 112017028331 A2 BR112017028331 A2 BR 112017028331A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
receptors
bind
human
relates
Prior art date
Application number
BR112017028331A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Humphreys David
Anthony Griffin Robert
Jane Peters Shirley
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112017028331A2 publication Critical patent/BR112017028331A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017028331A 2015-07-06 2016-07-06 proteínas de fusão que se ligam a receptores fc humanos BR112017028331A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1511787.2A GB201511787D0 (en) 2015-07-06 2015-07-06 Proteins
PCT/EP2016/065914 WO2017005767A1 (en) 2015-07-06 2016-07-06 Fusion proteins which bind to human fc receptors

Publications (1)

Publication Number Publication Date
BR112017028331A2 true BR112017028331A2 (pt) 2018-09-11

Family

ID=54013529

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028331A BR112017028331A2 (pt) 2015-07-06 2016-07-06 proteínas de fusão que se ligam a receptores fc humanos

Country Status (10)

Country Link
US (1) US20180194856A1 (enExample)
EP (1) EP3319991A1 (enExample)
JP (1) JP7097293B2 (enExample)
CN (1) CN108473571B (enExample)
AU (1) AU2016290523B2 (enExample)
BR (1) BR112017028331A2 (enExample)
CA (1) CA2991363A1 (enExample)
EA (1) EA201890225A1 (enExample)
GB (1) GB201511787D0 (enExample)
WO (1) WO2017005767A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016139006A (ru) 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
SG11201900427PA (en) 2016-07-22 2019-02-27 Gliknik Inc Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
JP7351835B2 (ja) * 2017-12-14 2023-09-27 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
EP3765492A1 (en) * 2018-03-16 2021-01-20 Liverpool School of Tropical Medicine Chimeric fc receptor binding proteins and uses thereof
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
GB0922209D0 (en) * 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
AU2012392760C1 (en) * 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins
EP3114137A1 (en) * 2014-03-05 2017-01-11 UCB Biopharma SPRL Multimeric fc proteins
RU2016139006A (ru) * 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics

Also Published As

Publication number Publication date
CA2991363A1 (en) 2017-01-12
WO2017005767A1 (en) 2017-01-12
GB201511787D0 (en) 2015-08-19
CN108473571A (zh) 2018-08-31
EP3319991A1 (en) 2018-05-16
US20180194856A1 (en) 2018-07-12
AU2016290523B2 (en) 2022-08-25
AU2016290523A1 (en) 2018-01-18
CN108473571B (zh) 2022-04-15
EA201890225A1 (ru) 2018-06-29
JP7097293B2 (ja) 2022-07-07
JP2018519834A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
BR112018012707A2 (pt) inibidores da interação de menin-mll
UY36021A (es) Proteìnas fc multimèricas
MX391051B (es) Anticuerpos anti-cd47 y usos de los mismos.
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
BR112016023948A2 (pt) proteínas fc multiméricas
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112016020377A2 (pt) proteínas fc multiméricas
BR112017006178A2 (pt) região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
EA201890225A1 (ru) Слитые белки, которые связываются с fc рецепторами человека
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
SI3346995T1 (sl) Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
BR112018075222A2 (pt) anticorpos anti-tnfrsf25
MX2015013803A (es) Proteina de fusion de enlace al cartilago.
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
MX2016010215A (es) Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
EP3265108A4 (en) PEPTIDES AND COMPOSITIONS AS WELL AS USES THEREOF IN THE TREATMENT OF DISEASES

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: UCB BIOPHARMA SRL (BE)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]